Most commercial AI roadmaps fund the exciting use case first and the highest-leverage one last. This guide gives Heads of Commercial Excellence the right order, a ranked, sourced sequence for both Pharma and CPG, with the dollar impact behind each decision.
Eleven questions. Two industries. One sourced sequence.
95%
of enterprise gen AI pilots show no measurable P&L impact, despite an estimated $30 to 40B in enterprise spend.
MIT NANDA, 2025 · cited in the guideSeven guides, from the CEO agenda to the plant floor. Each is a ranked, sourced priority sequence, built on research from Bain, McKinsey, Deloitte, BCG, EY, ZS and MIT NANDA.
Eleven questions. Two industries. One sourced sequence. Free, no spam, no sales pitch first.
Backed by McKinsey, BCG, ZS, KPMG and MIT NANDA research
The guide is on its way to your inbox.